Blog
RSS FeedPosted by Michael Wonder on 31 Mar 2017
Proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) in the Hospital medicines list
31 March 2017 - PHARMAC is seeking feedback on a proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) through a provisional ...
Posted by Michael Wonder on 09 Mar 2017
Proposal to list a range of orthopaedic implants and associated products supplied by LMT Surgical Pty Ltd
9 March 2017 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated ...
Posted by Michael Wonder on 27 Feb 2017
Additional listings on the Pharmaceutical Schedule of a range of orthopaedic implants and associated products with Smith and Nephew Limited
27 February 2017 - PHARMAC is pleased to announce the approval of an amendment to the trauma agreement with Smith ...
Posted by Michael Wonder on 02 Feb 2017
Proposal to list orthopaedic hip and knee implants, cement and associated products on the Pharmaceutical Schedule
2 February 2017 - PHARMAC is seeking feedback on a proposal to list further ranges of orthopaedic implants and associated ...
Posted by Michael Wonder on 20 Dec 2016
Proposal to maintain full subsidy for gefitinib (Iressa) from 1 April 2017
20 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of funding for gefitinib ...
Posted by Michael Wonder on 18 Dec 2016
Proposal to list a range of orthopaedic implants and associated products supplied by Zimmer Biomet New Zealand
16 December 2016 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated ...
Posted by Michael Wonder on 08 Dec 2016
Proposal to amend listings in the National Immunisation Schedule
9 December 2016 - Following a request for proposals for the supply of various vaccines, issued on 15 February 2016, ...
Posted by Michael Wonder on 16 Nov 2016
Proposal to list oral betaine for rare disorder
16 November 2016 - PHARMAC is seeking feedback on a proposal to list betaine (Cystadane) resulting from a provisional agreement ...
Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...
Posted by Michael Wonder on 28 Oct 2016
Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use
28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...
Posted by Michael Wonder on 05 Sep 2016
Proposal related to second & third-line anti-VEGF treatments for ophthalmic use
5 September 2016 - PHARMAC has entered into provisional agreements with Novartis and Bayer and is seeking feedback on a ...
Posted by Michael Wonder on 10 Aug 2016
Proposal to award sole supply of venlafaxine hydrochloride
10 August 2016 - PHARMAC is seeking feedback on a proposal to award sole supply status in the community for venlafaxine hydrochloride ...
Posted by Michael Wonder on 28 Jul 2016
Over 100,000 people set to benefit from PHARMAC vaccines decisions
28 July 2016 - PHARMAC has today announced changes to funded vaccines, which will benefit an extra 100,000 people. ...
Posted by Michael Wonder on 12 Jul 2016
Proposal to award sole supply of metoprolol tartrate injection in the community and DHB hospitals
12 July 2016 - PHARMAC is seeking feedback on a proposal for a sole supply arrangement for Mylan New Zealand Limited’s ...